Last €26.89 EUR
Change Today -0.41 / -1.50%
Volume 400.0
RHO6 On Other Exchanges
SIX Swiss Ex
SIX Swiss Ex
As of 10:25 AM 08/1/14 All times are local (Market data is delayed by at least 15 minutes).

roche holdings ltd-spons adr (RHO6) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/27/14 - €28.75
52 Week Low
08/5/13 - €23.06
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

roche holdings ltd-spons adr (RHO6) Related Bloomberg News

View More Bloomberg News

roche holdings ltd-spons adr (RHO6) Details

Roche Holding AG operates in the pharmaceuticals and diagnostics businesses in Switzerland, European Union, and internationally. It discovers, develops, and provides diagnostic and therapeutic products and services that enable patients and healthcare professionals in the detection, prevention, diagnosis, treatment, and treatment monitoring of diseases. The company provides pharmaceutical products for various therapeutic areas comprising oncology, virology, inflammation, metabolic disorders, and central nervous system. In addition, it offers a portfolio of diagnostics products, such as blood glucose meters for diabetes patients; point-of-care testing devices for use in doctors’ offices; high-throughput analyzers for hospitals and commercial diagnostic laboratories; and start-of-the-art instruments and reagents for life science research. The company has a collaboration agreement with Astrazeneca Plc to develop a plasma-based companion diagnostic test to support AZD9291, a drug candidate that is in clinical development for treating non-small-cell lung cancer. Roche Holding AG was founded in 1896 and is headquartered in Basel, Switzerland.

85,080 Employees
Last Reported Date: 01/30/14
Founded in 1896

roche holdings ltd-spons adr (RHO6) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: SFr.5.1M
Compensation as of Fiscal Year 2013.

roche holdings ltd-spons adr (RHO6) Key Developments

Roche and AmorChem L.P. Enters into Collaboration to Discover Novel Small Molecule Disease-Modifying Therapy for Treatment of Steinert's Disease

Roche and AmorChem L.P., announced that they have entered into a collaboration to discover novel small molecule disease-modifying therapy for the treatment of myotonic muscular dystrophy 1, or Steinert's disease. Myotonic dystrophy is a progressive degenerative disease that affects an estimated 130,000 people in US, EU and Japan. There is currently no approved treatment available to slow or stop disease progression. The collaboration will focus on the development of novel small molecules capable of correcting the consequences of the splicing deficit caused by the myotonic dystrophy 1 gene mutation. Through this approach, some of the molecular alterations caused by the disease process may be corrected and the progression of disease may be curtailed. The enabling technology was developed by Dr. Pascal Chartrand, a principal investigator at University of Montreal, and licensed to AmorChem by Univalor, the university s technology transfer group. Discovery will take place at AmorChem s medicinal chemistry incubator, NuChem Therapeutics, and in Dr. Chartrand s laboratory. Roche will provide scientific support and will contribute R&D funding together with AmorChem. The partnership with AmorChem fits well into the company discovery externalization strategy, which aims to leverage external scientific excellence and experienced entrepreneurs to complement its internal portfolio of innovative drug programs.

AstraZeneca Enters into Cancer Diagnostic Test Collaborations with Roche and QIAGEN

AstraZeneca and Roche will be collaborating on developing a plasma-based companion diagnostic test to support AstraZeneca's drug candidate AZD9291, which is undergoing clinical development for non-small-cell lung cancer (NSCLC). Separately, AstraZeneca will also be partnering with QIAGEN (Netherlands) in developing a non-invasive diagnostic test that would help identify NSCLC patients that would be suitable for treatment with AstraZeneca's Iressa (gefitinib).

Advanced Biological Laboratories and Roche Diagnostics International Renew and Extend Their Collaboration Agreement to Promote Their Next-Generation Sequencing, Genotyping and Drug Resistance Products

Advanced Biological Laboratories announced the renewal of a non-exclusive collaboration agreement with Roche Diagnostics International for Europe, Middle East, Africa (EMEA) and Latin America (LATAM) territories. This collaboration agreement is intended to develop a strategy to promote ABL products especially its next-generation sequencing platform DeepChek(R) together with Roche's next generation sequencing systems (GS Junior and GS FLX+ Sequencing Systems) for molecular virology. The principal objectives of the collaboration are to provide its mutual customers with integrated sequencing and analysis systems delivering the required quality, sensitivity and meaningful genotyping and drug resistance reporting for personal healthcare. The collaboration has been extended from HIV to viral hepatitis B and C.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RHO6:GR €26.89 EUR -0.41

RHO6 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
General Electric Co $25.35 USD +0.20
Gilead Sciences Inc $91.50 USD -0.05
Johnson & Johnson $99.90 USD -0.19
Novartis AG SFr.79.55 CHF -0.80
Sanofi €78.91 EUR +0.29
View Industry Companies

Industry Analysis


Industry Average

Valuation RHO6 Industry Range
Price/Earnings 20.7x
Price/Sales 4.5x
Price/Book 12.6x
Price/Cash Flow 16.9x
TEV/Sales 3.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ROCHE HOLDINGS LTD-SPONS ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at